Keryx Biopharmaceuticals to Present at The 11th Annual JMP Securities Research Conference; $KERX

Keryx Biopharmaceuticals, Inc. (NASDAQ: KERX) is focused on the acquisition, development and commercialization of medically important pharmaceutical products for the treatment of renal disease. Keryx is developing ZerenexTM (ferric citrate), an oral, ferric iron-based compound that has the capacity to bind to phosphate and form non-absorbable complexes. The Phase 3 clinical program of ZerenexTM for the treatment of hyperphosphatemia (elevated phosphate levels) in patients with end-stage renal disease is being conducted pursuant to a Special Protocol Assessment (SPA) agreement with the FDA. Keryx is headquartered in New York City. Keryx is headquartered in New York City.

The Company announced that its CEO, Ron Bentsur, will be presenting at the 11th Annual JMP Securities Research Conference. The conference will be held at the Ritz Carlton Hotel in San Francisco. Mr. Bentsur's presentation is scheduled to take place on Tuesday, May 15, 2012 at 12:00 noon Pacific Time (3:00 p.m. Eastern).

A live audio webcast of Mr. Bentsur's presentation will be accessible from the Investor Information page of the Company's Website at http://investors.keryx.com. An archived version of the webcast will be available following the conclusion of the live presentation.

KERYX CONTACT:
Lauren Fischer
Director Investor Relations
Keryx Biopharmaceuticals, Inc.
Tel: 212.531.5965     
E-mail: lfischer@keryx.com

Read more at Seeking Alpha.